Similarly, the outcomes achieved by combination regimens involving multiple immune checkpoint blocking agents, such as ipilimumab plus nivolumab in solid tumors, including renal cell cancer (RCC), NSCLC, and melanoma, or involving platinum-based chemotherapy plus a PD-1 or PD-L1 inhibitor in NSCLC were not influenced by PD-L1 expression (10–13). Here, CD274 is linked to non-small cell lung carcinoma.